Tenvie Therapeutics Inc

10/27/2025 | Press release | Archived content

Alzforum highlight: Tenvie brain-penetrant NLRP3 inhibitor reverses hypothalamic inflammation to drive weight loss in obesity


As featured by Alzforum, Tenvie's research preprint showcases how our brain-penetrant NLRP3 inhibitor, TN-783, alleviates inflammation-driven microglial activation, allowing the hypothalamus to more appropriately regulate food intake. This restoration of metabolic control results in gradual, fat-preferring weight loss in obese mice.

Read the full article on Alzforum here!

Tenvie Therapeutics Inc published this content on October 27, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 16, 2026 at 09:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]